Fundraising Fox
Sofinnova Ventures
Venture capitalActively deployingMenlo Park · Seed–Late Stage · 48 people tracked
Also known as Sofinnova Investments, Inc. · Sofinnova Venture Partners
Find your way into Sofinnova Ventures
Sign up to see every warm intro you have to Sofinnova Ventures
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sofinnova Ventures team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Sofinnova concentrates on backing transformative biotech companies across their full lifecycle. The firm positions itself as a hands-on, experienced partner that supports founders from a company's inception through the stages of drug development, navigating the regulatory process, building the organization, and reaching a public offering. Its emphasis is on life sciences innovation, working collaboratively with entrepreneurs through every phase of growth.
Source: firm website, verified Oct 13, 2026.
Team · 48 people
from the firm's website & curated
Aneal Tenjarla is a Partner and Associate Portfolio Manager for Sofinnova BioEquities, concentrating on public investments in global biotechnology, pharmaceutical, and medical technology companies, with more than ten years in public healthcare investing. Before joining Sofinnova in 2019, he spent five years as a Senior Analyst at Citadel managing a healthcare-focused portfolio, and earlier worked as an Analyst at Point72 covering healthcare and as an investment banker at Greenhill focused on healthcare M&A. He holds an M.S. in Biotechnology from Johns Hopkins and a B.B.A. from the University of Texas at Austin.
Chris Carpenter is an oncology physician-scientist with over two decades of clinical and laboratory experience who joined Sofinnova in 2022, focusing on clinical-stage product companies in oncology, rare diseases, and specialty therapeutics. He previously served as Chief Medical Officer at CatamaranBio and Rubius Therapeutics, and led cancer epigenetics at GlaxoSmithKline as well as drug development work at Merck. He holds a B.S. from Stanford University and M.D. and Ph.D. degrees from the University of Southern California, and is board certified in internal medicine and medical oncology.
Eric Delbridge is a General Partner at Sofinnova Ventures, where he leads development of the firm's BioEquities strategy focused on public investments in global therapeutics companies. He joined Sofinnova in 2016 after managing market neutral therapeutics and healthcare portfolios at Balyasny Asset Management, and was previously a Partner at Spring Point Capital (formerly Botti Brown Asset Management) and a healthcare investment banker at Lazard and Credit Suisse. He holds an M.D. from Northwestern University, an M.B.A. from The Wharton School, and a B.A. in Classics from Yale University.
Hooman Shahlavi handles legal matters at Sofinnova, including the structuring, negotiation, and execution of initial and follow-on investments, restructurings, major corporate transactions, exits, and wind-downs, as well as compliance, fund formation, and risk and director liability issues. He joined the firm in 2007 after practicing as an attorney at O'Melveny & Myers (2003-2007) and Brobeck, Phleger & Harrison, where he worked on venture capital, M&A, and public offering transactions. He holds a J.D. from the University of California, Hastings College of Law and a B.S. in Business Administration from San Jose State University.
Jakob Dupont is a physician with over two decades of experience in oncology and other therapeutic areas, focused on developing therapies for high unmet medical needs. Before joining Sofinnova in 2023, he held senior R&D and medical leadership roles at Atara Biotherapeutics, Gossamer Bio, Genentech/Roche, and OncoMed Pharmaceuticals. He earned his M.D. from Cornell University's Weill Medical College and an M.A. in philosophy from New York University, and completed his oncology fellowship at Memorial Sloan Kettering Cancer Center.
Jim Healy has spent about twenty years investing at Sofinnova, backing thirty-two companies in the biotechnology and healthcare space, many of which have gone public or been acquired. He holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from UC Berkeley, and earned his MD and PhD in Immunology from Stanford University through the NIH Medical Scientist Training Program. Before Sofinnova, he worked at Bayer (Miles) and Sanderling, and has lectured on entrepreneurship at Stanford.
Jonathan Leff is a physician with over 25 years of clinical development experience in the biotechnology and pharmaceutical industry, advising companies on drug development from target identification through market approval. Before joining Sofinnova in 2020, he was SVP and Chief Medical Officer of Ascendis Pharma, EVP of Research and Development at InterMune (where he led development and US approval of Esbriet for idiopathic pulmonary fibrosis), and held CMO roles at KaloBios Pharmaceuticals and Halozyme Therapeutics, plus positions at Roche, Amgen, and Merck. He holds a B.A. in Chemistry and an M.D. from the University of Pennsylvania, and completed training in Internal Medicine and Pulmonary and Critical Care Medicine at the University of Colorado, Denver.
Lars Ekman is a global R&D executive and drug developer with more than 30 years of experience across executive, scientific, and clinical roles, and he brings his life science background to the investment team. Before joining Sofinnova in 2008, he was President of Research and Development at Elan, having earlier held R&D leadership at Schwarz Pharma AG and various senior scientific and clinical roles at Pharmacia (now Pfizer). He earned his MD and PhD from the University of Gothenburg, Sweden, and is a board-certified surgeon with a PhD in Experimental Biology.
Maha Katabi is a PhD in Pharmacology and CFA who built crossover public/private biotech investing platforms, focuses on clinical‑stage single‑asset radiopharmaceutical and targeted oncology companies, and chairs Exactis Innovation.
Maha Radhakrishnan is an industry executive with decades of experience in product development, commercialization, and global medical strategy across biotechnology and pharmaceutical companies. Before joining Sofinnova in 2024, she served as Consultant to the CEO at Dyne Therapeutics, Chief Medical Officer at Biogen, and Senior Vice President and Global Head of Medical for the Primary Care Business Unit at Sanofi, with earlier leadership roles at Bioverativ, Bristol Myers Squibb, United Health Group, and Cephalon. She holds an M.D. in internal medicine from the People's Friendship University in Moscow and a master's degree in Russian language.
Nathalie Auber has more than twenty years of private equity experience across financial reporting, operations, and deal structuring, and works with the investment team on financings, exit strategy, and valuations. She leads Sofinnova's Finance & Accounting team and administrative functions, having joined the firm in 1996. Earlier in her career she served as Director of Internal Audit at Catellus Development and spent seven years as an auditor with Deloitte and Touche in Paris and San Francisco.
Alex Chan joined Sofinnova's Finance Department in 2013 as Senior Accountant and became Controller in 2021, handling the day-to-day accounting for the firm and its funds. Before Sofinnova, he worked at an international public accounting firm providing assurance and advisory services to public and private companies in the IT and biotech sectors. He holds a B.A. in Economics from UCLA and is a Certified Public Accountant in California.
Amanda Phillips is an Executive Assistant at Sofinnova Investments, with experience in the venture capital and private equity industry. Her areas of work include event planning, office administration, calendaring, onboarding, and human resources. She holds a Bachelor of Arts in Human Development from California State University-Hayward.
Anastasia Voevodin joined Sofinnova BioEquities as an Analyst in 2024, where she focuses on public biotech investments. She previously worked as a Senior Research Associate at Avoro Capital covering public biotech, and as a management consultant at ZS Associates serving biotech clients. She holds a PhD in Chemistry from Columbia University and a BA in Chemistry with a Biomedical Engineering Science minor from Boston University.
Calvin Sternick joined Sofinnova BioEquities as an Analyst in 2026, working on public investments in healthcare services. He previously worked as an Analyst at Millennium Management covering areas such as contract research organizations, hospitals, laboratories, and managed care organizations, and served as Vice President of Managed Care & Facilities Equity Research at JPMorgan Chase. Earlier roles included healthcare equity research at TD Cowen and FBR Capital Markets and a structured finance valuation position at EY; he holds a B.S. in Accounting from Binghamton University.
David Kabakoff is a medicinal chemist with more than 30 years of experience leading technology and product development in the pharmaceutical, biopharmaceutical, and drug delivery fields. Before joining Sofinnova in 2007, he co-founded the cancer drug developer Salmedix, serving as Chairman and CEO until its acquisition by Cephalon, and previously held executive roles at Dura, Spiros Development, Corvas International, and Hybritech. He holds a PhD from Yale University and a BA from Case Western Reserve University.
Debbie Murray joined Sofinnova as Chief People Officer in 2020, where she leads strategic and operational initiatives tied to business performance goals. She previously served as Chief People Officer at BlueJeans Network and as Vice President at DataStax, Inc., where she oversaw human resources and business administration during the company's early growth. She holds a B.A. in Speech Communication from the University of San Diego.
Eric Hsu joined Sofinnova as an Analyst in 2025, focusing on biopharmaceutical company investments across multiple disease areas and therapeutic modalities. He earned a PhD in Neuroscience from Johns Hopkins University, where his research in Dr. Dwight Bergles' lab used microscopy methods to study non-neuronal cell signaling in the brain and the effects of ketamine on that signaling. He previously held a BA in Neuroscience from Washington University in St. Louis and served as a Venture Fellow for Insight Partners and Sofinnova.
Gina Baker joined Sofinnova in 2022 as a Compliance/Operations Manager, handling operations for Sofinnova BioEquities and helping oversee firm compliance. She previously served as Senior Finance Manager of the public equities division at Vista Equity Partners and has held compliance, finance, and operations roles at investment firms including SPO Partners and Apex Capital. She holds a B.S. in Business Administration with emphases in Accounting and Corporate Management from California State University, Hayward.
Jim Brody joined Sofinnova in 2016 as Chief Compliance Officer for the firm and Chief Operating Officer for Sofinnova BioEquities. He previously served as Chief Compliance Officer and Managing Director of Operations at Apex Capital, LLC, and held earlier roles at Pershing, Nollenberger Capital Partners, Wells Fargo Securities, and Robertson Stephens. He holds an M.B.A. from the University of San Francisco and a B.S. from the University of Oregon.
John Barrett is a Senior Analyst at Sofinnova BioEquities, where he works on public biotech investments across all therapeutic areas. He previously worked as a biotech analyst at Parkman Healthcare Partners covering SMid cap therapeutic areas and at Leerink covering SMid cap oncology. He holds a Ph.D. in Molecular Engineering from the University of Chicago and a B.S. in Biomedical Engineering from Boston University.
Kathy Du joined Sofinnova in 2025 as Vice President of Finance for the Public Equity team, overseeing the financial operations of Sofinnova Public Markets. She previously served as Chief Financial Officer at One01 Capital and held controller roles at Paradigm and Passport Capital. She earned a B.S. in Business Administration with an accounting emphasis from the University of California, Berkeley, and is an inactive Certified Public Accountant.
Katrin Viller joined Sofinnova as Vice President of Finance in 2024, where she oversees the financial aspects of Sofinnova Venture funds. She previously served as Head of Finance at Kleiner Perkins and held several roles at PricewaterhouseCoopers in Estonia and San Jose, including auditing asset management and life science clients. She holds a B.A. in International Business from Estonian Business School and is a Certified Public Accountant in California.
Mike Van joined Sofinnova as an Analyst in 2022 and became an Associate in 2024, where he focuses on biopharmaceutical companies and investments. He earned a PhD in Biology from Stanford University, working in Lacramiora Bintu's lab on CRISPR-based epigenome editing tools, and holds a BS in Biochemistry and Molecular Biology from UC Davis. During his time at Stanford he was a venture fellow at Sofinnova and consulted in roles at biotech companies including Maze Therapeutics, Octant, and Wearlinq.
Naomi Pacalin joined Sofinnova as an Analyst and became an Associate in 2025, where she works on biopharmaceutical company investments across multiple disease areas and therapeutic modalities. She holds a PhD in Bioengineering from Stanford University, where her research in Howard Chang's lab covered epigenomics and gene regulation using CRISPR epigenetic editing and single-cell sequencing. She also earned a BS in Biological Chemistry and a BA in Chemistry from the University of Chicago, and previously served as a Sofinnova Venture Fellow.
Nick Lenard joined Sofinnova BioEquities as an Analyst in 2025, where he works on public investments in biotechnology and pharmaceutical companies globally. He previously spent over four years on the sell side covering SMid and Large Cap Biotechnology, most recently as a Vice President at J.P. Morgan. He holds an M.A. in Biotechnology from Columbia University and a B.A. in Chemistry from Kenyon College.
Paul Chang is an Analyst who joined Sofinnova BioEquities in 2025, where he works on public investments in medical technology and diagnostics. He previously served as an Investment Associate at TPG Growth, sourcing healthcare investments and supporting portfolio companies, and before that was an investment banker at Goldman Sachs covering healthcare M&A and financing. He holds a BS in Finance with a minor in English Literature from New York University.
Perry Nisen is a physician scientist with experience in drug discovery and development, focusing on pre-clinical and clinical companies in oncology, neuroscience, and immunology/inflammation. He joined Sofinnova in 2018 and previously served as CEO of the Sanford Burnham Prebys Medical Discovery Institute and held senior roles at GlaxoSmithKline, including SVP of Science and Innovation, interim Chief Medical Officer, and Oncology Therapy Area Head, as well as a cancer research leadership role at Abbott Laboratories. He earned a BS from Stanford University and an MD/PhD from the Albert Einstein College of Medicine.
Rachel Urrutia is a Finance & HR Coordinator at Sofinnova Investments. She has experience as a Finance & HR Coordinator and Executive Assistant across the venture capital, private equity, and biotechnology sectors.
Ray Bower joined Sofinnova in 2022 as Portfolio Manager of the Synergy Fund, concentrating on biotechnology and therapeutics. His earlier career included work as a medical director of a primary care clinic and in biologic product strategy at Centocor, followed by sell-side work at Citigroup, a partner and analyst role covering healthcare at Lee Munder Capital Group in Boston, running a biotech portfolio at TIAA CREF, and serving as Principal at Adenium Research. He holds a Bachelor of Medical Science and an M.D. from the University of Alberta and an MBA from the Wharton School at the University of Pennsylvania.
Seth Filbrun joined Sofinnova as an Associate in 2026 with Sofinnova BioEquities, where he works on public biotech investments. He previously worked as an Equity Research Associate at Stifel Financial covering small- and mid-cap biotech companies in immunology & inflammation and endocrinology, and before that as a Senior Consultant at Simon Kucher. He holds a Ph.D. in Analytical Chemistry from Georgia State University, an M.S. in Chemistry from Illinois State University, and a B.S. in Chemistry from Miami University.
Smita Chowdhri joined Sofinnova BioEquities as a Controller in 2026, handling accounting and finance for the public equity team. She previously served as Controller at Intrinsic Edge Capital Management and held roles at Gen II Fund Services, Jump Trading, Jump Capital, Wolverine Asset Management, and Navigant Consulting, where her work spanned fund accounting, investor reporting, regulatory compliance, and forensic accounting. She holds a Bachelor of Science in Finance, Accounting, and Business Process Management from Indiana University and is a CPA in Illinois.
Surin Kim joined Sofinnova in 2021 as a Financial Analyst, handling fund accounting and tax matters. He previously worked as a Tax Senior at BDO USA, LLP, focusing on tax issues related to alternative investments, and earlier served as a private banker at Mirae Asset Securities (Daewoo Securities) in South Korea. He holds a Master of Science in Taxation from Golden Gate University and a Bachelor's degree in Business Administration from Inha University.
Founder mafia
4 people who came through Sofinnova Ventures went on to found or lead other companies.
What they invest in
from 129 of 221 portfolio companiesBiotech ×118Healthtech ×57Medical Devices ×45Deep Tech ×13Digital Health ×12AI & Machine Learning ×7Data & Infrastructure ×3Hardware ×3
HQs:United States×101Denmark×2France×2United Kingdom×2Israel×2Netherlands×2
Who they back
founder profiles across 54 portfolio companiesFounding team size:solo founder×302 founders×163 founders×24+ founders×6
Where their founders studiedfrom 36 founders with education data
Massachusetts Institute of Technology ×4Harvard University ×3KU Leuven ×3Tulane University ×2Université Louis Pasteur (Strasbourg I) ×2University of California, Berkeley ×2University of Michigan ×2Utrecht University ×2
What their founders studiedfrom 35 founders with field-of-study data
Life Sciences ×18Medicine ×10Chemistry ×6Engineering ×5Business & Management ×3Computer Science ×3Economics ×2Finance & Accounting ×2
Where their founders worked beforefrom 42 founders with career history
Galapagos ×9Harvard Medical School ×4Aligos Therapeutics ×3Johnson & Johnson ×3Broad Institute of MIT and Harvard ×2Flexus Biosciences ×2Janssen Europe, Middle East & Africa (EMEA) ×2
19 founders hold a PhD · 2 hold an MBA (of 38 with degree data)
Investments · 221 tracked
founders shown can be your intro pathBy year:2026 · 62025 · 62024 · 72023 · 52022 · 22021 · 82020 · 42019 · 52018 · 62017 · 22016 · 32015 · 675 dated
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Founder)inEric Morgen(Founder)inDov Goldstein(Executive Officer)in
BoardPatrick Enright(Director)in
Board seatJames Healy· per SEC Form D
Co-investorsAndreessen HorowitzElad GilFelicis VenturesGreen Sands EquityIA Seed VenturesLongitude Capital+19 more
BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security.
AI & Machine LearningBiotechCybersecurityDeep TechDefense TechHardwareNess Ziona
Jonathan Solomon(Chief Executive Officer)inMerav Bassan(Chief Development Officer)inMarina Wolfson(Chief Financial Officer)inJesse Goodman(Director)Alan Moses(Director)Jonathan Leff(Director)
Board seatJonathan Leff· per SEC Form D · $3.3M raise · filed Jan 2026
Co-investorsAMR Action FundBaruch Future VenturesNSG VenturesOrbiMedSBI JI Innovation Advisory Ltd.Seventure Partners+2 more
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in
Board seatDavid Kabakoff· per SEC Form D
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan Capital+4 more
Seaport Therapeutics develops therapeutics and medicines.
BiotechMental HealthBoston, US
Daphne Zohar(Founder, CEO & Board Member)inSteven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)Michael Chen(Executive Officer)inLana Gladstein(Executive Officer)inAntony Loebel(Executive Officer)in
Board seatJames I. Healy· per SEC Form D
Co-investorsARCH Venture PartnersForesite CapitalGeneral AtlanticHAWKTAILPureTech HealthCPP Investments+3 more
Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant.
BiotechDigital HealthMedical DevicesSouth San Francisco, US
Marshall Fordyce(Executive Officer, Director)in
BoardBeth Seidenberg(Director)inKurt von Emster(Director)inPatrick Enright(Director)inAndrew Cheng(Director)
Board seatMaha Katabi· per SEC Form D
Co-investorsKleiner PerkinsLongitude CapitalAbingworthSofinnova Venture Partners
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)inJoseph Monahan(Executive Officer)inHugh Davis(Executive Officer, Director)inJames Loerop(Executive Officer)
Co-investorsAisling CapitalAPERTURE Venture PartnersF-Prime CapitalForesite CapitalRA CapitalSofinnova Venture Partners+1 more
Anavex Life Sciences is a clinical-stage biopharmaceutical company developing oral therapeutics for central nervous system disorders, including Alzheimer's disease, Rett syndrome, and Fragile X syndrome.
BiotechHealthtechPortola Valley, US
Alexandre Vamvakides(Executive Officer)Axel Paeger(Board Member (founder))Harvey Lalach(Executive Officer, Director)inGeorge Tidmarsh(Executive Officer, Director)Terrie Kellmeyer(Interim Chief Executive Officer)inChristopher U. Missling(Executive)in
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Founder)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)
BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)
Co-investorsCardinal PartnersEcoR1 CapitalViking GlobalDomain AssociatesDomain PartnersPolaris Partners+2 more
Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.
BiotechHealthtechMedical DevicesSan Francisco, US
Dr. Edgar G. Engleman(Founder)
Co-investorsPfizer Venture InvestmentsPivotal Life SciencesRA CapitalSamsara BioCapitalVivo CapitalNan Fung Life Sciences+3 more
Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer.
BiotechHealthtechMedical DevicesRedwood City, US
Dennis M. Lanfear(Executive Officer, Director)Denny Lanfear(Founder)inAlan C. Herman(Executive Officer)inJean-Frederic Viret, Ph.D.(Executive Officer)Peter K. Watler, Ph.D.(Executive Officer)Barbara K Finck, M.D.(Executive Officer)
Co-investorsF-Prime CapitalHEALTHCARE ROYALTY PARTNERSVenrock
Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.
BiotechDeep TechMedical DevicesCambridge, US
Feng Zhang(Founder)inGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in
Co-investorsEcoR1 CapitalGV (Google Ventures)Viking GlobalAtlas VentureDeerfield Management CompanyFlagship Ventures+2 more
Enanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need.
Biotech
Jay R. Luly(President, Director and Chief Executive Officer)Yat Sun Or(Chief Scientific Officer)Scott T. Rottinghaus(Chief Medical Officer)inMatthew P. Kowalsky(Chief Legal Officer and Corporate Secretary)Tara L. Kieffer(Chief Product Strategy Officer)inBrendan Luu(Chief Business Officer)in
Co-investorsSaints CapitalAbbVie
Kiniksa is a global biopharmaceutical company that discovers and develops novel therapies for patients with unmet medical needs, with a focus on cardiovascular diseases and related conditions.
BiotechMedical DevicesHamilton
THOMAS W BEETHAM(Executive Officer)inSanj K. Patel(Chief Executive Officer and Chairman of the Board)
BoardSTEPHEN R BIGGAR(Director)FELIX J BAKER(Director)G. BRADLY COLE(Director)RICHARD S LEVY(Director)
Co-investorsDeerfield Management CompanySofinnova Venture Partners
Ligand is a royalty aggregator that finances late-stage clinical development and commercialization programs for biopharmaceutical companies.
BiotechFintechLa Jolla, US
Brook Byers(Co-founder)inMATTHEW W. FOEHR(Director)JOHN L. HIGGINS(Executive Officer, Director)inMATTHEW KORENBERG(Director)inCHARLES S. BERKMAN(Director)inTodd Davis(Chief Executive Officer)in
Co-investorsSignet Healthcare PartnersVenrock
A Spanish-language blog that publishes articles on health and medicine topics, such as flu prevention and vaccination recommendations, for general readers.
BiotechMedia & EntertainmentAustin, US
Matthew Winkler(Director)Sinil Kim(Executive Officer)inPaul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)
BoardMichael Powell(Director)
Co-investorsNew Enterprise Associates (NEA)Pfizer Venture InvestmentsCorrelation VenturesOrbiMedOUP (Osage University Partners)Pfizer Ventures
Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.
BiotechDigital HealthHealthtechMedical Devices
Matthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)
Co-investorsBain Capital Life SciencesCheyenne VenturesClaremont Creek VenturesForesite CapitalHarmony PartnersHBM Healthcare Investments+4 more
Hugh Griffith(Founder)in
Co-investorsSofinnova PartnersScottish Enterprise
Protalix is a biopharmaceutical company that develops and manufactures innovative pharmaceutical products, including treatments for orphan and rare diseases.
BiotechHealthtechMedical DevicesKarmiel, IL
Moshe Bashan(President and Chief Executive Officer)Dror Bashan(President and Chief Executive Officer, Director)in
Co-investorsPontifax Venture Capital
Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins.
BiotechDun Laoghaire, Co. Dublin, US
Tran B. Nguyen(Executive Officer)Arthur W. Homan(Executive Officer)Karin L. Walker(Executive Officer)inTara Nickerson, Ph.D.(Executive Officer)Wagner M. Zago, Ph.D.(Executive Officer)Carol D. Karp(Executive Officer)in
Co-investorsInvescoRA CapitalWellington Management
Rapport is a biopharmaceutical company developing novel therapeutics.
BiotechHealthtechMedical Devices
Abe Ceesay(President)Cheryl GaultinDr. SevignyAbraham N. Ceesay(President and Chief Executive Officer and Director)Steven Paul David Bredt(Founder)
Co-investorsARCH Venture PartnersCapital GroupJohnson & Johnson Innovation – JJDCThird Rock Ventures
Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Matthew Henn(President and Chief Scientific Officer)inJohn Aunins(Executive Officer)inEric D. Shaff(Executive Officer)inDavid Cook(Executive Officer)inRoger J. Pomerantz(Executive Officer, Director)inRichard N. Kender(Executive Chair and Interim Chief Executive Officer)
Co-investorsFlagship PioneeringRA CapitalFidelity Investments
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
BiotechWaltham, US
John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in
BoardDennis Podlesak(Director)inIvor Royston(Director)
Co-investorsAisling CapitalATEM Capital FundAvoro Capital AdvisorsBioBritDelos CapitalEcoR1 Capital+6 more
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.
BiotechDeep TechMedical DevicesCambridge, US
Bharatt Chowrira(Executive Officer)inMichael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)inPaul Miller(Executive Officer)inAoife Brennan(Executive Officer)inTodd Shegog(Executive Officer)in
Co-investorsAtlas VentureCLI VenturesNew Enterprise Associates (NEA)NSG VenturesPfizer Venture InvestmentsSolasta Ventures+1 more
Aledia develops next-generation MicroLED display technology based on 3D nanowires grown on silicon, operating a pilot line and high-volume production facility.
Deep TechHardwareSemiconductorsGrenoble, FR
philippe GILET(Founder)in
Co-investorsBraemar Energy VenturesIntel CapitalDemeterIngka InvestmentsSupernovaTEL Venture Capital, Inc.+3 more
ASSIA develops core technology for broadband internet access and network optimization, serving telecommunications service providers and network operators.
AI & Machine LearningCloud ComputingData & InfrastructureDeep TechEnterprise SoftwareRedwood City, US
John M. Cioffi(CEO and Chairman of the Board)inAssia Cioffi(Executive Vice President and Co-founder)in
Co-investorsDTCPSofinnova PartnersStanford UniversitySwisscom VenturesPartners for Growth
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in
BoardCorey . Goodman(Director)inJonathan Leff(Director)in
Co-investorsvenBio PartnersMRL Ventures FundCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso Ventures+8 more
Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology.
BiotechHealthtechMedical DevicesSan Francisco, US
Yi Larson(Founder and CEO)Geoff Gilmartin(Chief Medical Officer)Eric Hu(Chief Business Officer)
Co-investorsForbionNovo HoldingsSanofi Ventures
Aphage develops AI and sensor technologies to identify, track, and classify physical threats across borders, infrastructure, and transportation networks for government and security organizations.
AI & Machine LearningBiotechDefense TechGovTechGaithersburg, IL
Gregory L. Merril(Executive Officer, Director, Promoter)Carl R. Merril(Executive Officer, Director)in
BoardEvan Loh(Director)Jana Jensen(Director)Raymond L. Martz(Director)
Board seatJonathan Leff· per SEC Form D · $30M raise · filed Jun 2023
Co-investorsHackensack Meridian Health Bear's DenMaryland TEDCOTEDCOAMR Action FundDeerfield Management Company
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)inJohn Kincaid(Chief Scientific Officer)inDavis Ryman(Executive Officer)inMicah Zajic(Executive Officer)inIan Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Board seatLars Ekman· per SEC Form D
Co-investorsCoastCapCTI Life Sciences Fund L.P.Felix JahnFJ LabsLuma GroupvenBio Partners+2 more
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in
Board seatDavid Kabakoff· per SEC Form D
Co-investorsAdjuvant CapitalAvestria VenturesBrace PharmaCanaan PartnersGaingelsGV (Google Ventures)+6 more
__Twitter.png)
NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
BiotechCrestwood, US
Pascal Deschatelets(Executive Officer)inCedric Francois(Executive Officer, Director)in
BoardGerald Chan(Director)Stephanie O'Brien(Director)Alec Machiels(Director)A. Sinclair Dunlop(Director)
Board seatMaha Katabi· per SEC Form D
Co-investorsAvoro Capital AdvisorsEMBL VenturesEpidarex CapitalF-Prime CapitalKeyhorse CapitalSolasta Ventures+1 more
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Board seatJames Healy· per SEC Form D
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHBM Healthcare InvestmentsHBM PartnersHongShan Capital Group+4 more
.png)
ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.
BiotechHealthtechMedical DevicesSan Diego, US
Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)
Board seatJonathan Leff· per SEC Form D · $55M raise · filed Sep 2021
Co-investorsNextech InvestOrbiMedRA CapitalSR One Capital Management
Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.
BiotechHealthtechBaltimore, US
Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)
BoardRobert Jackson(Director)
Board seatJonathan Leff· per SEC Form D · $2.8M raise · filed Aug 2023
Co-investorsBiotech Investments S.R.Oi&i Biotech FundOUP (Osage University Partners)Deerfield Management Company
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.
BiotechSolana Beach, US
Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)in
BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)
Board seatMaha Katabi· per SEC Form D · $56M raise · filed Feb 2016
Co-investorsAstellas Venture Management LLCMission Bay CapitalMission BiocapitalOUP (Osage University Partners)Pfizer Venture InvestmentsUS Venture Partners
Elektrofi is a biotech company developing an ultra-high concentration microparticle formulation platform that enables subcutaneous delivery of biologic medicines such as monoclonal antibodies.
BiotechDeep TechHealthtechMedical DevicesBoston, US
Chase Coffman(Chief Executive Officer & Co-founder)inSam Huang(Director)Jason Norris(Co-founder)Charles L. Cooney(Director)Andrew Goldberg(Director)Constatine Chinoporos(Director)
Board seatNoel Jee· per SEC Form D · $112.3M raise · filed Oct 2024
Co-investorsBiotechnology Value FundNovo HoldingsCatalio Capital Management, LPCharlotte Angel FundGeneral CatalystRA Capital+1 more
Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.
BiotechHealthtechSan Diego, US
Mark W. Surber, Ph.D.(Executive Officer, Director)Richard G. Vincent(Executive Officer)
BoardMichael J. Kamdar(Director)Daniel D. Burgess(Director)
Board seatJonathan Leff· per SEC Form D · $189.2M raise · filed Oct 2023
Co-investorsF-Prime CapitalNorwest Venture PartnersRiverVest Venture Partners
Acquired by Lisata Therapeutics alongside a $225 million concurrent private placement.
BiotechSan Francisco, US
Mark Joing(Executive Officer)inChristine Garrett(Executive Officer)inJosh Lehrer(Executive Officer, Director)inEthan Weiss(Executive Officer)inCaitlin Murray(Executive Officer)
BoardJeff Tong(Director)
Board seatMaha Katabi· per SEC Form D
Co-investorsAlpha Wave GlobalThird Rock VenturesvenBio PartnersForbion
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.
BiotechDeep TechHealthtechSouth San Francisco, US
Cameron Pitt(Executive Officer, Director)inDerek Metzger(Executive Officer)
BoardPerry Nisen(Executive Officer, Director)inMaria Fardis(Director)inRajul Jain(Director)in
Board seatMaha Katabi· per SEC Form D
Co-investorsFinchley Healthcare VenturesLongitude CapitalVida VenturesBiotechnology Value FundFrazier Life Sciences
Seattle, US
Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)inJoseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)
BoardRobert Shepler(Director)in
Board seatDavid Kabakoff· per SEC Form D · $35.7M raise · filed Jul 2023
Co-investors5AM VenturesArboretum VenturesF-Prime CapitalTelegraph Hill PartnersHealthQuest Capital
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
BoardAaron Royston(Director)in
Board seatMaha Katabi· per SEC Form D
Co-investorsLifeSci Venture PartnersSamsara BioCapitalScion Life SciencesTCG CrossovervenBio PartnersVersant Ventures+4 more
Route 92 Medical develops neurointervention catheter systems and devices aimed at improving outcomes for neurovascular patients, including stroke treatment.
BiotechHardwareHealthtechMedical DevicesSan Mateo, US
Dr. Chou(Founder & Chief Executive Officer)Cindy Lynch(Executive Officer)inDr. Joey English(Chief Medical Officer)Tony Chou(Founder)in
BoardJack Lasersohn(Director)inTamir Meiri(Director)
Board seatNoel Jee· per SEC Form D · $50M raise · filed Apr 2026
Co-investorsNovo HoldingsThe Vertical GroupNorwest Venture PartnersRunway Growth CapitalUS Venture PartnersSectoral Asset Management+1 more
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Board seatMaha Katabi· per SEC Form D
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesViking GlobalWestlake Village BioPartners+11 more
A pharmaceutical company that develops medicines and vaccines for patients globally.
BiotechHealthtechMedical DevicesCambridge, US
WYLIE W. VALE(Director)JOHN KNOPF(Executive Officer, Director)STEVEN ERTEL(Executive Officer)ROBERT STEININGER(Executive Officer)inKEVIN F. MCLAUGHLIN(Executive Officer)inMATTHEW L. SHERMAN(Executive Officer)
Co-investorsBessemer Venture PartnersForesite CapitalLightstone VenturesLowercarbon CapitalVenrockCollaborative Fund
Jean-Paul Clozel(Founder)
Co-investorsRidgeback CapitalJohnson & Johnson Innovation – JJDC
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical DevicesBedminster, US
CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)David Endicott(CEO of Alcon)in
Co-investorsAlta PartnersAvoro Capital AdvisorsForesite CapitalOUP (Osage University Partners)
BiotechCincinnati, US
Robert Shalwitz(Executive Officer)Joseph Gardner(Founder)inDuane Nash(Director)Kevin Peters(Executive Officer)Steve Pakola(Executive Officer)Ian A.W. Howes(Executive Officer)
Co-investorsCincyTechAlly Bridge GroupOrbiMed
AFYX is a biopharmaceutical company focused on reformulation and repurposing of existing pharmaceuticals for conditions including head and neck cancer, labor induction, cluster headaches, and pain and addiction.
BiotechHealthtechMedical DevicesHørsholm, DK
Dr. Claus J. Møller-San Pedro(CEO)
Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.
BiotechHealthtech
Co-investorsBain Capital Life SciencesRA CapitalAtlas VentureForbion
Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.
BiotechHealthtechBrookline, US
Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in
BoardEd Mathers(Director)inKush Parmar(Director)in
Co-investors5AM VenturesEcoR1 CapitalNew Enterprise Associates (NEA)Pivotal Life SciencesRA CapitalCowen Healthcare Investments+2 more
BiotechHealthtechMedical Devices
Co-investorsNew Enterprise Associates (NEA)
Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Carlos Quezada-Ruiz(Chief Medical Officer)in
Co-investorsBain Capital Life SciencesTCG CrossoverWellington Management
Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease.
BiotechHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsFountain Healthcare PartnersLongitude CapitalSignet Healthcare Partners
Developing a new class of antifungal medicine to overcome limitations of current therapies.
Co-investorsBioBritGolden SeedsKeiretsu ForumPappas CapitalRiverVest Venture Partners3x5 Partners+4 more
Anesiva is a biopharmaceutical company developing Nexletol for diet management.
Biotech
Anthera produces makeup and skincare products made in France with natural, non-toxic ingredients that are cruelty-free and vegan.
ConsumerWellness & FitnessFrance, FR
Co-investorsPappas CapitalVantagePoint Capital Partners
Apeiron Therapeutics is a biotech company developing small-molecule therapeutics with a focus on immuno-oncology and oncology drug discovery.
AI & Machine LearningBiotechDeep TechHealthtechBurlingame, US
Mingxi Li(CEO)inFred Aswad(Chief Scientific Officer)in
Co-investorsPanacea Venture
Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.
BiotechDeep TechHealthtechLongevity
Nils Regge(Co-Founder & General Partner)in
Co-investorsBLN CapitalCoastCapFelix JahnFJ LabsKfW CapitalQuery Capital+5 more
Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small molecule and monoclonal antibody combination therapies for people with cancer.
BiotechHealthtech
Juan Jaen(Co-founder & President)inTerry Rosen(Co-founder & Chief Executive Officer)inBob Goeltz(Chief Financial Officer)inRichard Markus(Chief Medical Officer)inCarolyn Tang(General Counsel)Yvonne Gehring(SVP, Human Resources)
Co-investorsAisling CapitalDecheng CapitalDroia VenturesEcoR1 CapitalForesite CapitalGV (Google Ventures)+4 more
ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.
BiotechHealthtechMedical DevicesOslo, NO
Roy Larsen(Scientific Co-Founder)Øyvind Bruland(Scientific Co-Founder; SAB Chairman)Margaret Yu(Chief Medical Officer)inPhilippe Dasse(Chief Technical Officer)inAmra Demirovic(Chief Human Resources Officer)inNicole Hadas(Chief Legal Officer)
Co-investorsB Capital GroupB4 CapitalF-Prime CapitalAlexandriaB CapitalOmega Funds+2 more
.jpeg){kind=logo}
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)Martin Auster(Executive Officer)in
Co-investorsVivo CapitalAisling CapitalAvoro Capital AdvisorsForesite CapitalRA CapitalSofinnova Partners
A biotechnology company developing new therapies for patients with high unmet medical needs.
Biotech
Co-investorsDolby Family VenturesLifeSci Venture PartnersThe W FundViking GlobalCommodore CapitalFranklin Templeton+6 more
Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases that cause vision loss.
BiotechDeep TechMedical DevicesAustin, US
Co-investorsLightstone VenturesWellington ManagementHatteras Venture Partners
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
BiotechSan Diego, US
Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in
BoardCarl Gordon(Director)
Co-investorsDelos CapitalForesite CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMed+6 more
BiotechSan Leandro, US
Steve Abella(Chief Medical Officer)inGraeme Currie(Chief Operating Officer)inStephen W. Lau(President, Chief Executive Officer, and Treasurer)inKenneth Schwartz(Executive Officer)inEric Yuen(Executive Officer)inMarten Steen(Director)in
Co-investorsEQT Life SciencesHealthCapInkefSectoral Asset ManagementYsios Capital
AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.
BiotechHealthtechMedical DevicesSan Diego, US
Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)inRamin Farzaneh-Far(Executive Officer)inJustin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)
Co-investorsFinchley Healthcare VenturesPfizer Venture InvestmentsRA CapitalVida VenturesAlexandriaForbion
Activating the immune system to recognize and destroy tumor cells.
BiotechCambridge, US
Art Krieg(Executive Officer, Director)Barry Labinger(Executive Officer, Director)Chuck Abdalian(Executive Officer)David Mauro(Executive Officer)Karen Brennan(Executive Officer)Charles Yon(Executive Officer)
Co-investorsDecheng CapitalF-Prime CapitalLongitude CapitalNovo HoldingsvenBio Partners
BiotechNewton Centre, US
Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)
BoardScott Minick(Director)inTodd T. Foley(Director)inVincent Miles(Director)Ansbert K. Gadicke(Director)in
Co-investorsHEALTHCARE ROYALTY PARTNERSAbingworthARCH Venture PartnersMPM BioImpact
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)Andy Orth(Chief Executive Officer)in
Co-investorsAN Venture PartnersARCH Venture PartnersViking GlobalAltitude Ventures Management, LlcCasdin CapitalFidelity Investments+5 more
BiotechChelsea, US
RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)inMARK IWICKI(Executive Officer, Director)inMARTIN FREED(Executive Officer)in
BoardROB HOPFNER(Director)in
Co-investorsCanaan PartnersLongitude CapitalBay City CapitalFountain Healthcare PartnersOrbiMedRA Capital
Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.
BiotechHealthtechMedical DevicesJersey City, US
Clarke Atwell(Co-Founder and Chief Operating Officer)inHenry Rath(Executive Officer)Susan Orr(Executive Officer)inStephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)
Co-investorsCatalio Capital Management, LPRA CapitalCatalio Capital ManagementNovo HoldingsSamsara BioCapital
Co-investorsVerizon Ventures
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)inMarie De Vulder(Chief Legal Officer Co-founder)inGuy Peeters(Chief Financial Officer Co-founder)inJohn-Paul Gallivan(Head of Development Co-founder)inFabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in
Co-investorsFinchley Healthcare VenturesLongwood FundLuma GroupBAM ElevateForbionNovo Holdings+2 more
Crocus Technology, now part of Allegro MicroSystems, develops XtremeSense TMR (Tunnel Magnetoresistance) magnetic sensing technology used in integrated current and position sensor ICs.
Co-investors+ND CapitalVentechVentech ChinaCEA Investissement
DealForma provides a data platform and analyst support for biopharma business development teams to research partnerships, deals, funding trends, and therapeutic areas.
BiotechData & InfrastructureHealthtechSaaS
Chris
Co-investorsTinySeedAlgerRA CapitalREDMILERTW Investments L.P.
Gilead discovers, develops, and delivers therapeutic medicines for life-threatening diseases, with focus on virology, oncology, and inflammation across 35+ countries.
BiotechHealthtechMedical DevicesPalo Alto, US
Ravindra Majeti(Director)Irving Weissman(Director)Eric Jensen(Executive Officer)
BoardChristopher Schaepe(Director)inJeffrey Bird(Director)Dennis Henner(Director)
Co-investorsBluebird VenturesGV (Google Ventures)Lightspeed Venture PartnersClarus VenturesSutter Hill VenturesWellington Management
Galera Therapeutics is a biotechnology company developing antibody-based and other therapeutics.
BiotechHealthtechMedical DevicesMalvern, US
Mel Sorensen(Executive Officer, Director)inJoel Sussman(Executive Officer)inJeffery L. Keene(Executive Officer)inDennis P. Riley(Executive Officer)inJon T. Holmlund(Executive Officer)Robert A. Beardsley(Executive Officer, Director)in
Co-investorsBioGenerator VenturesNew Enterprise Associates (NEA)
Nexoplex Bio develops immunotherapies designed to target tumors through recognition of HLA-peptide complexes using multi-specific antibodies, aimed at cancers including certain lung, gastric, esophageal, head and neck, and cervical cancers.
BiotechHealthtechSan Carlos, US
Andrew Allen(Executive Officer, Director)inVassiliki Economides(Executive Officer)Matthew Hawryluk(Executive Officer)inWayne(CEO)Rachel(VP of Operations)Shefali Agarwal(Director)
Co-investorsFrazier Life SciencesGV (Google Ventures)The Column GroupREDMILEVersant Ventures
The site at this domain is a consumer guide to online casinos in Florida, publishing reviews, rankings, and explanations of gambling laws, bonuses, payment methods, and responsible play.
Media & EntertainmentSan Mateo, US
Anukool Lakhina(Executive Officer, Director)
BoardJose Suarez(Director)Amit Shah(Director)inBrian Wilcove(Director)Andrew Fligel(Director)Michael LaJoie(Director)
Co-investorsQuestMark PartnersTransLink CapitalArtiman VenturesGoldman SachsIntel CapitalSingTel Innov8 Pte Ltd.
Novartis is a pharmaceutical company that develops and commercializes prescription medicines and therapies across therapeutic areas including oncology, cardiovascular disease, and immunology.
BiotechMedical Devices
Co-investorsCambridge Innovation Capital
HealthtechWaltham, US
Adam Gridley(Executive Officer, Director)Peter Greenleaf(Executive Officer, Director)
BoardJoshua Baltzell(Director)Kevin Rakin(Director)Garheng Kong, M.D., Ph.D.(Director)John J. Johnson(Director)
Co-investorsFOUNDATION MEDICAL PARTNERSSplit Rock Partners
Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings.
BiotechDigital HealthMedical DevicesBrisbane, US
Carlos A. Schuler(Executive Officer, Director)inJohn S. Patton(Executive Officer, Director)inRangachari Narasimhan(Executive Officer, Director)Grace Colon(Executive Officer, Director)inMiller Samantha(Executive Officer)
BoardMcCarthy Reenie(Director)
Co-investorsAsset Management CompanyHealthCapDeerfield Management Company
BiotechBoston, US
Axel Bolte(Executive Officer, Director)inReinaldo Diaz(Director)Joseph Schlessinger(Executive Officer, Director)
BoardEdward Mathers(Director)Rob Hopfner(Director)inMartin Edwards(Director)
Co-investorsLongitude CapitalNew Enterprise Associates (NEA)Pivotal Life SciencesSanofi Ventures
InterMune was a Brisbane, California biotechnology company focused on pulmonology and fibrotic diseases, best known for developing pirfenidone (Esbriet) to treat idiopathic pulmonary fibrosis.
daniel welchinScott Harkonen(Founder)
Co-investorsRidgeback CapitalSanderling VenturesNew Enterprise Associates (NEA)
Iterum provides appliance management infrastructure for institutional landlords, combining procurement, maintenance, and data analytics to optimize operational efficiency and reduce costs.
Data & InfrastructureEnterprise SoftwarePropTechSaaSLondon, GB
Jon Holden(CEO)inFelix Dahlke(CTO)
Co-investorsClearance Venture PartnersSustainable VenturesCanaan PartnersFrazier Healthcare PartnersNew Leaf Venture Partners
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.
BiotechDigital HealthHealthtechMedical DevicesDublin, US
Michael W. Dunne(Executive Officer, Promoter)inCorey N. Fishman(Executive Officer, Director, Promoter)inJudith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)
BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)
Co-investorsBay City CapitalCanaan PartnersAdvent Life SciencesDolby Family VenturesFrazier Life SciencesSofinnova Venture Partners
Jounce Therapeutics was a Cambridge, MA clinical-stage biopharmaceutical company developing cancer immunotherapies, including antibodies targeting ICOS and LILRB2/ILT4, guided by a biomarker-driven discovery platform.
BiotechCambridge, US
Kim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)inRichard Murray(Executive Officer, Director)
BoardRobert Tepper(Director)inCary Pfeffer(Director)inRobert Kamen(Director)in
Co-investorsBoutique Venture PartnersGENERAL INCEPTIONNextech InvestVenture Capital Investment ManagementThird Rock VenturesWellington Management
Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.
Co-investorsARCH Venture PartnersPivotal Life SciencesAlexandriaPureTech HealthWellcome Trust
Kiromic BioPharma was a clinical-stage biotherapeutics company using an AI-driven platform to develop allogeneic Gamma Delta T-cell immunotherapies for solid tumors, including lead candidate Deltacel-01 for lung cancer.
Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network.
Advanced ManufacturingBiotechHealthtechMedical Devices
Co-investorsARCH Venture PartnersCross Creek AdvisorsPfizer Venture InvestmentsSignet Healthcare Partners
BiotechRadnor, US
Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)
BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesCanaan PartnersConnecticut InnovationsDomain AssociatesFlare Capital Partners+1 more
Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.
BiotechMedical DevicesUtrecht, NL
Ton Logtenberg(Executive Officer, Director)inMark Throsby(Executive Officer)inHui Liu(Executive Officer)inJohn Crowley(Executive Officer)inL. Andres Sirulnik(Executive Officer)inLex Bakker(Executive Officer)in
Co-investorsAvoro Capital AdvisorsPfizer Venture InvestmentsRA Capital
HealthtechNew Orleans, US
Mark Heiman(Executive Officer)inDale Pfost(Executive Officer, Director, Promoter)
BoardDon Marvin(Director)Richard Montgomery(Director)Ross Barrett(Director)John Elstrott(Director, Promoter)
Co-investorsBayern KapitalDCVC (Data Collective)FemHealth VenturesPangaea Ventures Us Inc.
Molecular Templates, Inc. was a clinical-stage biopharmaceutical company formerly based in Austin, TX.
BiotechAustin, US
Co-investorsHitecVision Advisory ASLongitude CapitalSolasta Ventures
Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.
BiotechEvanston, US
Joseph R. Moskal(Executive Officer)inAmin Khan(Executive Officer)inJames Schulz(Executive Officer)Ronald M. Burch(Executive Officer)Norbert Riedel(Executive Officer, Director)Ashish Khanna(Executive Officer)
Co-investorsCota CapitalEcoR1 CapitalLatterell Venture PartnersAdams Street Partners
BiotechCambridge, US
Richard Gaynor, M.D.(Executive Officer)inRobert Ang, M.D.(Executive Officer)Yasir Al-Wakeel(Executive Officer)inEric Lander(Director)Hugh Dowd(Executive Officer, Director)
BoardCary Pfeffer, M.D.(Director)
Co-investorsNextech InvestClal Biotechnology IndustriesThird Rock VenturesWellington Management
Nextwave Pharma markets Quillivant XR, a prescription central nervous system stimulant used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6 and older.
BiotechHealthtechNew Jersey, US
Co-investorsBay City CapitalF-Prime Capital
NorthSea Therapeutics is a clinical-stage biopharmaceutical company developing oral fatty acid-derived therapies for liver and metabolic diseases, including intestinal failure-associated liver disease (IFALD), severe hypertriglyceridemia, and MASH.
BiotechDigital HealthHealthtech
Co-investorsNew Science VenturesvenBio PartnersYsios CapitalBGVNovo HoldingsBioGeneration Ventures+1 more
Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US
Arthur T. Sands(Executive Officer, Director)inGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)
BoardDavid Goeddel(Director)inMark Goldsmith(Director)
Co-investorsBain Capital Life SciencesEcoR1 CapitalForesite CapitalGeneral AtlanticThe Column GroupWellington Management+1 more
The page is a Vietnamese-language sports streaming site (90Phut TV / 90Phutr.tv, also called Vaoroi TV) offering free live football streaming links, match schedules, standings, results, news, and betting odds.
Media & EntertainmentSports TechHà Nội, VN
Co-investorsAisling CapitalM VenturesNew Enterprise Associates (NEA)Sofinnova Partners
Ocular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions.
BiotechDigital HealthHealthtechMedical DevicesBedford, US
Amarpreet Sawhney(Director)Kevin Hanley(Executive Officer)Michael Goldstein(Executive Officer)inDaniel Bollag(Executive Officer)Antony Mattessich(Executive Officer, Director)inDonald Notman(Executive Officer)in
Co-investorsAscension VenturesSV Health InvestorsTop Corner CapitalAgent Capital
OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages.
BiotechMedical DevicesNew York, US
Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)Bing Yuan, Ph.D., MBA(Co-Founder, Chief Executive Officer)Eric Slosberg, Ph.D.(Co-Founder, Chief Development Officer)Andy Fu, PharmD, MBA(Co-Founder, Chief Business Officer)
Co-investorsOrbiMedCatalio Capital Management, LPF-Prime CapitalDe Novo VenturesInsight PartnersNVIDIA
BiotechNew York, US
David Guyer(Executive Officer, Director)Glenn Sblendorio(Executive Officer, Director)Mike AtiehinDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)
Co-investorsSV Health InvestorsClarus VenturesSV Life Sciences
Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases.
BiotechHealthtechLa Jolla, US
Preston Klassen(Executive Officer)inJoseph Hagan(Executive Officer)Michael Narachi(Executive Officer, Director)Thomas Cannell(Executive Officer)
BoardEckard Weber(Director)Brian H. Dovey(Director)in
Co-investorsCross Creek AdvisorsMontreux Equity PartnersNew Enterprise Associates (NEA)Domain AssociatesDomain Partners
Perception Neuroscience is a clinical-stage biotech developing R-ketamine (PCN-101), a single-isomer glutamatergic modulator being studied as a rapid-acting antidepressant for patients with treatment-resistant depression.
BiotechDigital HealthHealthtechMental Health
Co-investorsWPSS Investments
HealthtechSan Francisco, US
Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)inLeon Chen, Ph.D.(Director)Carol Gallagher(Director)inJoshua Resnick, M.D.(Director)
BoardMichael Powell(Director)
Co-investorsMission Bay CapitalMission BiocapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)OrbiMedSofinnova Venture Partners
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)in
BoardPETER THOMPSON(Director)inSRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Co-investorsAccess BiotechnologyMission BiocapitalSR One Capital ManagementMission Bay CapitalNew Leaf Venture PartnersOrbiMed+1 more
BiotechMalvern, US
Mark Lupher(Executive Officer)Dominick C. Colangelo(Executive Officer, Director)
BoardJames W. Broderick, M.D.(Director)Geert-Jan Mulder(Director)inJohn Friedman(Director)inHarold R. Werner(Director)
Co-investorsEaston CapitalEaston Capital Investment GroupForbion
Developing disease-modifying therapeutics for diseases of protein processing, with a lead program in cystic fibrosis.
Co-investorsAvoro Capital AdvisorsF-Prime CapitalNew Enterprise Associates (NEA)Sanofi Ventures
Venture-backed ophthalmic biopharmaceutical company developing LFA-1 antagonists for dry eye disease; acquired by Shire in 2013.
Co-investorsRho Ventures
BiotechHealthtechMedical DevicesNew York, US
Charles Pfizer
Co-investorsRidgeback Capital
BiotechLa Jolla, US
Allison E. Hulme(Executive Officer, Director)inRandall E. Woods(Executive Officer, Director)inPeter T. Slover(Executive Officer)Gerald T Proehl(Director)John E Geltosky(Director)Jim E. Heppell(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Aerovate Therapeutics, Inc.Atsena Therapeutics, Inc.Bolt TherapeuticsCleveland DiagnosticsGyroscope Therapeutics LtdNeurana PharmaceuticalsAchaogenAcrotech PharmaceuticalsActimis PharmaceuticalsAdeona BiotechAdvanced Oxygen TherapeuticsAeovianAlimera SciencesAmarantus BioscienceAmplyx PharmaceuticalsAnthera PharmaAnthera PharmaceuticalsAntheriX TherapeuticsApollohealAppulse CorporationAralez PharmaceuticalsAsyndetan HoldingsAthena TherapeuticsAtsena TherapeuticsAudentes TherapeuticsAuris PharmaceuticalsAurismedicalAveXisBioDelivery SciencesCatalyst BiosciencesCaveoGelCebixChameleon PharmaCheckmate PharmaChimera TherapeuticsCinCorCinCor PharmaCompugen TherapeuticsCoTherixDauntlessphEar PharmaceuticalsEdgeEdge TherapeuticsEntasis TherapeuticsEntellus MedicalFirstaidshottherapyGenitopeHeartSpan TechnologiesHumanigenHumanity TherapeuticsHyperion TherapeuticsHyperiontxInnocollInozymeIntellikineIntransaIntrepidabioKalyotaKaruna TherapeuticsLifegen BiotechnologiesMedeor TherapeuticsMeru TherapeuticsMetacelMisonixNeos TherapeuticsNeuranapharmaNexigen BiopharmaNucleonyx PharmaceuticalsOrexigenPharmaSonicsPhocéa PharmaPregLemProdigy BiotechProgenics PharmaceuticalsRainierrxRaptor PharmaceuticalsReata PharmaceuticalsRetinal ImplantRXSTATUSSaegis PharmaceuticalsSangamo BiotherapeuticsSeagenSensei BiotherapeuticsSerica Technologies
Browse all 221 investments with full details →
▶21 more tracked companies
Sorbent TherapeuticsSpark TherapeuticsSparktxSybios CorporationSyros PharmaceuticalsTensysmedicalTransgenomicTranslate BioTriusrxTSROVelosbioVera TherapeuticsVersartisVesalius TherapeuticsVicepttxVion PharmaceuticalsVisen PharmaVisen PharmaceuticalsXyloCor TherapeuticsYmabsZS Pharma
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 53
23 IPOs · 30 acquisitions · showing 44BioAge LabsNASDAQ: BIOABiomxNYSE: PHGENextCureNASDAQ: NXTCSeaport TherapeuticsNASDAQ: SPTXVeratxNASDAQ: VERAAclaris TherapeuticsNASDAQ: ACRSAnavex Life SciencesNASDAQ: AVXLaTYR PHARMANASDAQ: ATYRBolt BiotherapeuticsNASDAQ: BOLTCoherus BiosciencesNASDAQ: CHRSEditas MedicineNASDAQ: EDITEnanta PharmaceuticalsNASDAQ: ENTAKiniksaNASDAQ: KNSALigandNASDAQ: LGNDMirna TherapeuticsOTC: SYBXNateraNASDAQ: NTRANucanaNASDAQ: NCNAProtalixNYSE: PLXProthenaNASDAQ: PRTARapport TherapeuticsNASDAQ: RAPPSeres TherapeuticsNASDAQ: MCRBSyndax PharmaceuticalsNASDAQ: SNDXSynlogicOTC: SYBXApellis Pharmaceuticalsacq. by BiogenAerovatetxacq. by Jade BiosciencesAlimera Sciencesacq. by ANI PharmaceuticalsAlimerasciencesacq. by ANI PharmaceuticalsBioDelivery Sciencesacq. by Collegium PharmaceuticalEdge Therapeuticsacq. by PDS Biotechnology Corp.Entellus Medicalacq. by StrykerForty Seven Incacq. by GileadInozymeacq. by BioMarin Pharmaceutical Inc.InterMuneacq. by RocheMisonixacq. by BioventusNeos Therapeuticsacq. by Aytu BioScience (later Aytu BioPharma)Nextwavepharmaacq. by Tris PharmaProgenics Pharmaceuticalsacq. by Lantheus HoldingsProteostasis Therapeuticsacq. by Yumanity TherapeuticsRaptor Pharmaceuticalsacq. by Horizon PharmaReata Pharmaceuticalsacq. by BiogenSaegis Pharmaceuticalsacq. by H. Lundbeck A/SSeagenacq. by PfizerSeattle Geneticsacq. by PfizerSerica Technologiesacq. by Allergan
Portfolio news
latest coverage across their companies
Veratx · manilatimes.net · Sep 1, 2026
Arrivent · stocktitan.net · Aug 12, 2026
Syndax Pharmaceuticals · aol.com · Aug 12, 2026
Ligand · markets.businessinsider.com · Aug 6, 2026
Claris Bio · glance.eyesoneyecare.com · Aug 3, 2026
NextCure · grafa.com · Jul 14, 2026
BioAge Labs · newmarketpitch.com · Jul 13, 2026
Ascendis Pharma A/S · stocktitan.net · Jun 29, 2026
Fund performance · per public LP disclosures · 4
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Sofinnova Venture Partners IXLPs: California State Teachers' Retirement System | 2014 | — | 7.2% | 1.47x | 1.01x |
| SOFINNOVA VENTURE PARTNERS VIII LPLPs: Oregon Public Employees Retirement System, California State Teachers' Retirement System, University of Texas Investment Management Company | 2011 | — | 21.9% | 1.66x | 1.66x |
| Sofinnova Venture Partners VIILPs: Oregon Public Employees Retirement System | 2007 | — | 14.7% | 1.71x | 1.71x |
| Sofinnova Venture Partners VILPs: Orange County Employees Retirement System | 1999 | — | -19.8% | 0.10x | 0.15x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings · 3
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Seaport Therapeutics | 5.2% | $18.00 | May 2026 | $49.2M |
| BioAge Labs | 4.8% | $18.00 | Sep 2024 | $29.5M |
| Rapport Therapeutics | 3.9% | $17.00 | Jun 2024 | $23.7M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Nov 2024
Disclosed stake · filed Sep 2024
Disclosed stake · filed Jun 2024
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Sofinnova Ventures made?
- Sofinnova Ventures has 221 tracked investments, 53 of which have exited, including 14 dated in the last 24 months.
- What stage does Sofinnova Ventures invest at?
- Sofinnova Ventures invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Sofinnova Ventures's typical check size?
- Sofinnova Ventures typically writes checks of $100K – $15M.
- What sectors does Sofinnova Ventures focus on?
- Sofinnova Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Sofinnova Ventures located?
- Sofinnova Ventures is headquartered in Menlo Park, US.
- Does Sofinnova Ventures lead rounds?
- Sofinnova Ventures typically participates in rounds rather than leading them.
- Who does Sofinnova Ventures co-invest with?
- Sofinnova Ventures most often shares deals with RA Capital, Foresite Capital, New Enterprise Associates (NEA), among 162 tracked co-investors.
Images
Co-investors · 30
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds companies in the life sciences and biotechnology sector, focused on developing novel medicines and therapeutics.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Forbion is a global venture capital firm focused on advancing biotech innovations and other sustainable solutions aimed at improving human and planetary health.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Pivotal Life Sciences is a global healthcare investment firm backing companies developing high-impact therapeutics for major unmet medical needs, operating across venture capital, venture building, and public equity strategies.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
▶18 more co-investors
SR One Capital ManagementSanofi VenturesAbingworthGeneral CatalystJohnson & Johnson Innovation – JJDCMorgenthalerVida VenturesWestlake Village BioPartnersAndreessen HorowitzSequoia CapitalB Capital GroupEntrepreneur FirstCambridge Innovation CapitalNovartis Venture FundFrazier Healthcare PartnersVantagePoint Capital PartnersBoxOne VenturesACORN BIOVENTURES
Firms observed investing alongside Sofinnova Ventures, from public investor directories. Shared companies are the overlap with Sofinnova Ventures's recorded portfolio.
Similar investors
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.
Novo Holdings is the investment arm of the Novo Nordisk Foundation and a leading life science investor that also manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity assets.